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vided a consent form after receiving verbal and written details regard-
ing the procedures adopted in the study, which was approved by the
Ethics Committee of our Institution (UFF/Huap #0038.0.258.000-08).
This trial is registered in ClinicalTrials.gov (NCT01500343). Patients
were excluded if there was current or recent (last 4 weeks) use of cor-
ticosteroids, non-steroid anti-inﬂammatory, probiotics or antibiotics;
clinical signs or symptoms of infection, independent of location; severe
life threatening illness, inﬂammatory or autoimmune diseases, cancer,
renal disease, intestinal surgery, artiﬁcial heart valve, history of rheu-
matic heart disease or infective endocarditis; lactose intolerance or in-
tolerance to dairy products. Patients, physicians and staff, including
echocardiographists, were blinded for all steps of the study. Clinical re-Table 1
Comparison of laboratorial and echocardiographic parameters before and after 3-months
of probiotic or placebo therapy.
Group Baseline After treatment P value
Mean ±SD Mean ±SD
S. boulardii
Glycemia 100.67 ±13.1 94.7 ±3.9 0.803
Total cholesterol 150.83 ±27.3 143.2 ±39.7 0.010
Leukocyte count 5885.0 ±1563 5783.3 ±1616 0.916⁎
Creatinine 1.12 ±0.4 0.9 ±0.2 0.051⁎
Uric acid 6.15 ±1.3 5.1 ±1.3 0.014
hsCRP (mg/dL) 0.498 ±0.5 0.27 ±0.3 0.116⁎
LVEF (%) 39.0 ±6.5 45.6 ±7.6 0.005
Left atrial diameter 4.49 ±0.8 4.2 ±0.9 0.044
Placebo
Glycemia 96.89 ±17.6 105.1 ±23.2 0.087
Total cholesterol 174.22 ±31.3 172.2 ±36.8 0.603
Leukocyte count 6723.3 ±689.9 7264.4 ±1174 0.214⁎
Creatinine 0.97 ±0.1 0.96 ±0.1 0.905⁎
Uric acid 5.6 ±1.2 5.59 ±0.9 0.930
hsCRP (mg/dL) 0.22 ±0.3 0.65 ±0.6 0.011⁎
LVEF (%) 38.9 ±9.6 43.3 ±10.2 0.173
Left atrial diameter 4.3 ±0.9 4.5 ±0.7 0.079On the last decade, there has been a progressive increase in a num-
ber of publications on microbiota and therapeutic potential of
probiotics. Recent studies have been suggesting that consuming
probiotics may have beneﬁts on cardiovascular system, as the improve-
ment on blood pressure control by a modest degree [1]. Heart failure
(HF) patients present low grade inﬂammation that participates on the
progression of cardiac remodeling [2]. Moreover, when the heart is fail-
ing,myocytes showenhanced expression of inﬂammatorymediators, as
adhesion molecules, tumor necrosis factor (TNF)-a, interleukin-6 and
others [2]. Chronic HFpatients usuallymanifest disturbance in intestinal
motility and villi absorption, with impairment of tissue perfusion and
edema [3,4]. These intestinal alterations promote proliferation of en-
teropathogenic ﬂora and increase in bacterial (endotoxin) translocation
[5]. Under this cardio-intestinal interaction, inﬂammatory cytokines
and chemokines appear to be elevated in direct proportion to worsen-
ing of symptoms and cardiac function, as estimated by left ventricular
ejection fraction (LVEF) [2]. Therefore, we have investigated the impact
of a 3-month daily therapywith Saccharomyces boulardii for chronic sys-
tolic HF outpatients.
Patients admitted to the HF outpatient clinic at the Antonio Pedro
University Hospital were recruited through a clinical screening. Twenty
HF patients NYHA class II or III, with LVEF b50%, were randomized to
probiotic preparation with S. boulardii (1000 mg per day) or placebo,
for 3-month oral daily therapy. For all patients, HF drug therapy wass, Rio de Janeiro, RJ 21045-900,
. Moscavitch).
.not modiﬁed in the previous 4 weeks of inclusion. Eligible patients pro-
search unit staffs were responsible for delivering treatment supply
(probiotic or placebo), according to a randomized numbered list. Four
patients were excluded because of therapy discontinuity. For datahsCRP = high-sensitivity C reactive protein; LVEF = left ventricular ejection fraction.
Bold-emphasismeans that the variable has reached statistical signiﬁcance, as deﬁned by p
value b0.05.
⁎ Obtained with Wilcoxon signed-rank test.
Fig. 1. Dot-plot of atrial diameter (upper), LVEF (middle) and hsCRP (bottom), before and after 3 months of probiotic or placebo therapy.
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butionwere estimatedwith the Shapiro–Wilk test. Non-parametric var-
iables were leukocyte count, creatinine and hsCRP. Differences for
normally distributed variables were analyzed with T test and paired
Student's T test. Non-normally distributed variables (hsCRP, leukocyte
count and creatinine) were analyzed with the Mann–Whitney test
and Wilcoxon signed-rank test. The adopted statistical signiﬁcance
was b0.05.
At baseline, both groups were similar and did not present differ-
ences among demographic, laboratorial parameters and echocardio-
gram. The group treated with probiotic presented a reduction in total
cholesterol levels (p = 0.010), uric acid levels (p = 0.014), left atrial
diameter (p = 0.044), and an improvement in LVEF (p = 0.005),
seen in Table 1. Placebo group showed an increase in hsCRP levels,
after 3-months (p = 0.011), seen in Fig. 1. Comparison of parameter
variations (delta) before and after therapy showed that the group
treated with probiotic had a signiﬁcant reduction in left atrial diam-
eter (probiotic: −0.27 vs. placebo: +0.22; p = 0.007), uric acid
(probiotic:−1.08 vs. placebo: +0.02; p = 0.009), hsCRP (probiotic:−0.23 vs. placebo: +0.44; p = 0.031), and creatinine levels (probi-
otic:−0.22 vs. placebo:−0.01; p= 0.047). The proposed treatment
with this probiotic was safe and well tolerated, as there were no re-
ports on side effects or adverse events according to the study
patients.
A recently published study has evaluated the effect of probiotic ad-
ministration (Lactobacillus rhamnosus) in a rat model after inducing a
myocardial infarction through an occlusion of sustained coronary artery
for 6weeks, comparingwith placebo. This study showed that rats under
probiotic regimen have presented a signiﬁcant attenuation of left ven-
tricular hypertrophy, as showed by tissue weight and gene expression
of atrial natriuretic peptide, and an improvement on LVEF [6]. Addition-
ally, another animal study has showed that treating spontaneously hy-
pertensive rats with probiotic-fermented purple sweet potato yogurt
is beneﬁcial, as suggested by reduced cardiomyocyte apoptosis and im-
provement in myocardial and interstitial remodeling [7]. Our study has
showed that patientswith chronic systolic HF submitted to a short-term
probiotic therapy present an improvement in LVEF (p = 0.005) and a
reduction on left atrial diameter (p = 0.044), seen in Fig. 1.
350 A.C. Costanza et al. / International Journal of Cardiology 179 (2015) 348–350Several other authors also have been tried tomodulate intestinalmi-
crobiota as therapy for cardiovascular diseases. An interesting pilot
study used antibiotic regimen to eradicate Gram-negative intestinal
ﬂora in chronic stable severe HF patients [8]. In spite of not being ran-
domized or placebo-controlled, it has showed that selective decontam-
ination of intestinal tractwas able to reducemonocyte CD14 expression,
intracellular cytokine production and to improve peripheral endothelial
function. In another study [9], the antibiotic vancomycin, which also re-
duces effectively intestinal microbiota, was used to treat rats before
myocardial infarction. Same study [9] also tested a probiotic preparation
with Lactobacillus plantarum. Interestingly, rats treated with vancomy-
cin presented a reduction of 27% in myocardial infarct size with im-
provement of 35% in mechanical function on post-ischemic recovery,
comparedwith untreated controls. Similarly, rats treatedwith probiotic
showed a reduction of 29% inmyocardial infarct sizewith improvement
of 23% in mechanical function on post-ischemic recovery [9]. Our pilot
study has demonstrate that chronic systolic HF patients treated with
S. boulardii for 3-months presented a reduction on biochemical and in-
ﬂammatory biomarkers (creatinine, uric acid, hsCRP), and also an im-
provement on cardiovascular functioning (left atrial diameter, LVEF),
compared with placebo group.
The probiotic preparation containing S. boulardiiwas donated by the
pharmaceutical company EMS,which had no role in the design, conduc-
tion of the study, data collection, patient management, data analysis; or
in the preparation, review, or approval of the manuscript.Conﬂict of interest
The authors report no relationships that could be construed as a con-
ﬂict of interest.
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